The FLUCOP consortium, funded by IMI, evaluated the use of cell-mediated immunity and neuraminidase assays as tools for assessing influenza vaccine performance. Artemis was involved in the development of novel analytical approaches to population-based evaluation of influenza vaccine effectiveness, in particular in older adults.
Artemis Bioservices assists you with the development of experimental recombinant protein vaccines.
Valid comparison of immunogenicity and efficacy across vaccine candidates or preclinical models will be obtained by conducting head-to-head analysis using a standardized assay that has equivalent sensitivity and specificity for different host species. Artemis Bioservices can advise you on the choice of commercially available assay, or can assist you by developing tailored-made assays that are highly optimized for sensitivity, specificity, precision, reproducibility, and robustness.